所在团队为国际肺癌协会候任主席所在团队，获得国际肺癌协会肺癌治疗团队奖，引领国内肺癌诊疗技术发展。

1. 趋化因子结合蛋白DARC通过促进肺癌干细胞VE-Cadherin内化抑制血管生成拟态的新功能研究，20ZR1447100,上海市自然科学基金.

2. 单细胞全转录组测序建立肺癌抗PD1/PD-L1免疫预测模型研究，上海市申康，SHDC2020CR4001

3. PD-1 单抗治疗一线化疗后进展的晚期肺肉瘤样癌的单臂、开放、探索性II 期临床研究,FKLY20019

4.  CSCO君实肿瘤免疫研究基金，PD-1单抗JS001联合白蛋白紫杉醇用于一线化疗失败的广泛期小细胞肺癌的疗效和安全性的单臂观察性研究，Y-JS2019-070

5.  国家自然科学基因青年项目，趋化因子结合蛋白DARC在调节肺癌干细胞促血管生成中的作用，81402381

6.  上海市科委引导类项目：可溶性趋化因子结合蛋白DARC在抗肺癌血管生成中的应用 编号：114119a7600

1. Fengying Wu,#Tao Jiang,# Gongyan Chen, et al. Multiplexed imaging of tumor immunemicroenvironmental markers in locally advanced or metastatic non-small-celllung cancer characterizes the features of response to PD-1 blockade pluschemotherapy. Cancer Commun. 2022 Oct.（IF：16.2, Q1）

2. Fengying Wu;Jue Fan; et al; Single-cell profiling of tumor heterogeneity and themicroenvironment in advanced non-small cell lung cancer, Nat Commun., 2021.May,12(1): 2540 （IF：17.6，Q1）

3. Fengying Wu;Wei Li; Wencheng Zhao; et al. Synchronous ground-glass nodules showed limitedresponse to anti-PD1/PD-L1 therapy in patients with advanced lungadenocarcinoma, Clin Transl Med., 2020, 10: e149 （IF：11.49，Q1）

4. Fei Zhou†, Jianguo Sun†, LingyunYe†,…. Fengying Wu*,Caicun Zhou* and Guanghui Gao*. Fibronectin promotes tumor angiogenesis andprogression of non-small-cell lung cancer by elevating WISP3 expression viaFAK/MAPK/ HIF-1α axis and activating wnt signaling pathway. Exp Hematol &Oncol,  2023.12:61（共通讯，IF：10.9, Q1）

5. Zhiming Zhao; Ningyue Zhang; et al; Fengying Wu;Liang Zhang; Insulin-like growth factor-1 receptor induces immunosuppression inlung cancer by upregulating B7–H4 expression through the MEK/ERK signalingpathway, Cancer Lett., 2020, 485: 14（共通讯，IF：8.6，Q1）

6. Youwei Lu; Fengying Wu; Qiuyi Cao; Yu Sun; MoliHuang; Jing Xiao; Bin Zhou; Liang Zhang*; B7-H4 is increased in lungadenocarcinoma harboring EGFR-activating mutations and contributes toimmunosuppression, Oncogene., 2022.Jan, 41(5): 704-717 （IF：9.86，Q1，共一）